ABOUT RISEN
Risen Group
Corporate Culture
Development History
Management Team
Partners
R&D
PIPELINE
CLINICAL
RP901
RP902
RP903
NEWS
Company news
IP granted
Publications
CONTACT US
CAREERS
Working at Risen
Job opportunities
Employee welfare
繁体
简体
RISEN PHARMA
ABOUT RISEN
Risen Group
Corporate Culture
Development History
Management Team
Partners
R&D
PIPELINE
CLINICAL
RP901
RP902
RP903
NEWS
Company news
IP granted
Publications
CONTACT US
CAREERS
Working at Risen
Job opportunities
Employee welfare
First in China: ANGPTL3 siRNA drug developed Risen and TopAlliance jointly approved for clinical trial.
Release time:2023-02-03 Click:310
Hot News
Risen's innovative KRAS drug research result has been selected for presentation at the AACR Annual Meeting 2024 in San Diego, California!
Risen found status in the "2023 Hurun Global Cheetah Enterprise List"
Congratulations! Risen successfully acquired Biosafety Laboratory level 2 (BSL-2) qualification.
Congratulations! Risen laned in “KPMG China Biotech Future Sector 50 Ranking”
Congratulations! Risen was entitled as a "special and innovative" small to medium-sized enterprise in Shanghai
Congratulations! Risen successfully acquired the identification as the national high-tech enterprise!
Shanghai Zhangjiang R&D Center.
Suzhou Industrial Park R&D Center.
Shanghai Lingang Industrial Base.
send mail
Copyright 2022 Risen(Shanghai) Pharma Tech Co., Ltd. All Rights Reserved
沪ICP备16020731号-1
Design by:
yushangweb